收藏切换
Molecular mechanism of decitabine in the treatment of chronic myelogenous leukemia with overexpression of ecotropic viral integration site 1
收藏切换
Wei HE, Wei LI, Fuxing LI*, Xiaotian XIE
World Clinical Drug | 2023, 44(2) : 134 - 141
Less
收藏切换
World Clinical Drug | 2023, 44(2): 134-141
• Article •
Molecular mechanism of decitabine in the treatment of chronic myelogenous leukemia with overexpression of ecotropic viral integration site 1
Full
Wei HE, Wei LI, Fuxing LI*, Xiaotian XIE
Affiliations
  • Department of Pediatrics, Tongji Hospital of Tongi University, Shanghai 200065, China
Published: 2023-02-10 doi: 10.13683/j.wph.2023.02.006
Outline
收藏切换
Objective

To explore the effects of ecotropic viral integration site 1 (EVI1) overexpression on K562 cells, and the molecular mechanism of DNA methyltransferase inhibitor decitabine in the treatment of chronic myelogenous leukemia (CML) with high expression of EVI1.

Methods

Retrovirus vectors were used to transfect K562 cells, and the expression level of micro RNA (miR)-9, the methylation degree of miR-9 promoter sequence and the number of cell clones in empty vector group and EVI1 group were detected. K562 cells with high EVI1 expression were treated with decitabine and solvent to detect the expression level of miR-9, methylation degree of miR-9 promoter sequence, number of cell clones and cell cycle.

Results

Compared with the empty vector group and EVI1 group, the relative expression level of miR-9 was significantly decreased [(0.002 1±0.000 3) vs (0.003 4±0.000 3), P<0.01], and the methylation degree of miR-9 promoter sequence was significantly increased, cell proliferation was enhanced [(232.67±6.81) vs (124.67±5.03), P<0.01]. Compared with the solvent group, the expression level of miR-9 in decitabine group was significantly increased [(0.002 3±0.000 3) vs (0.000 7±0.000 1), P<0.01], and the methylation degree of miR-9 promoter was significantly decreased [(44.67±6.57)% vs (90.22±4.29)%, P<0.01], the cell proliferation ability was decreased [(173.67±12.06) vs (219.33±10.26), P<0.01], and the proportion of G0/G1 cells was increased [(59.25±1.20)% vs (50.45±1.06)%, P<0.05].

Conclusion

EVI1 down-regulates the expression of miR- 9 by increasing the methylation degree of miR-9 promoter, which may be one of the mechanisms of EVI1 participates in CML. Decitabine can reverse the methylation degree of miR-9 caused by EVI1 overexpression, and inhibit the cloning and proliferation ability of tumor cells, providing a theoretical basis for its use in the treatment of CML with EVI1 overexpression.

decitabine  /  ecotropic viral integration site 1  /  chronic myelogenous leukemia  /  molecular mechanism  /  micro RNA-9
何薇, 李威, 李福兴, 谢晓恬. 地西他滨治疗亲嗜性病毒整合位点1高表达的慢性髓细胞性白血病分子机制研究. 世界临床药物, 2023 , 44 (2) : 134 -141 . DOI: 10.13683/j.wph.2023.02.006
Wei HE, Wei LI, Fuxing LI, Xiaotian XIE. Molecular mechanism of decitabine in the treatment of chronic myelogenous leukemia with overexpression of ecotropic viral integration site 1[J]. World Clinical Drug, 2023 , 44 (2) : 134 -141 . DOI: 10.13683/j.wph.2023.02.006
Year 2023 volume 44 Issue 2
11
3
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.02.006
  • Receive Date:2022-08-28
  • Online Date:2026-11-18
  • Published:2023-02-10
Article Data
Affiliations
History
  • Received:2022-08-28
  • Revised:2022-12-12
Funding
Affiliations
    Department of Pediatrics, Tongji Hospital of Tongi University, Shanghai 200065, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.02.006
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT